UPDATE 1-Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027

(Adds company comments from conference call in paragraph 3 and 4)

May 18 (Reuters) - Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, Chief Executive Richard Francis said on Thursday.

Austedo is Teva's branded treatment for Huntington's Disease but the drug also helps those with movement disorder tardive dyskenisa.

Teva expects revenue from Austedo to reach $1.2 billion in 2023 from $971 million in 2022.

"We are going all in on Austedo," CEO Francis said at the company's investor day, adding that Teva plans to ramp up its investment towards the drug, including on a bigger sales force.

Before the conference call, Francis told reporters that only 15% of the 800,000 people suffering from tardive dyskenisa take medication.

"There's a huge unmet medical need and there's a huge opportunity for us to help those who are suffering from this condition," he said.

Francis also said he aims to keep Teva as a "generics powerhouse", although the company will trim its product line, while also growing its innovative drug pipeline. (Reporting by Steven Scheer in Jerusalem and Aditya Samal in Bengaluru; Editing by Kirsten Donovan and Shinjini Ganguli)